The challenge of incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods
Cost-effectiveness analyses (CEAs) that use patient-specific data on costs and health outcomes from a randomized controlled trial (RCT) are popular, yet such CEAs are often criticized because they neglect to incorporate evidence external to the trial. Although evidence directly defined on cost and health outcomes is often not transferrable across jurisdictions, evidence on biologic aspects of treatments such as the treatment effect can be transferred, and incorporating such evidence in the CEA can conceivably affect the results. Fully parametric Bayesian evidence synthesis for RCTbased CEAs is possible, but there are challenges involved in parametric modeling of cost and health outcomes and their relation with external evidence. A popular method for quantifying uncertainty in a RCT-based CEA is the bootstrap. It will be attractive to further expand this method for the incorporation of external evidence. To this end, we utilize the Bayesian interpretation of the bootstrap and derive the distribution for the cost and effectiveness outcomes after observing the current RCT data and the external evidence. We propose simple modifications of the bootstrap for sampling from such posterior distributions. We use data from a clinical trial and incorporate external evidence on the effect size of treatments to illustrate the method in action. Compared to the parametric models of evidence synthesis, the proposed approach requires fewer distributional assumptions, does not require explicit modeling of the relation between external evidence and outcomes of interest, and is generally easier to implement.
|Date of creation:||Aug 2012|
|Date of revision:|
|Contact details of provider:|| Postal: |
Phone: (0)1904 323776
Fax: (0)1904 323759
Web page: http://www.york.ac.uk/economics/postgrad/herc/hedg/
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost-effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787.
- Andrew H. Briggs & David E. Wonderling & Christopher Z. Mooney, 1997. "Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation," Health Economics, John Wiley & Sons, Ltd., vol. 6(4), pages 327-340.
- Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453, March.
- Glick, Henry A & Doshi, Jalpa A & Sonnad, Seema S & Polsky, Daniel, 2007. "Economic Evaluation in Clinical Trials," OUP Catalogue, Oxford University Press, number 9780198529972, March.
When requesting a correction, please mention this item's handle: RePEc:yor:hectdg:12/24. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Jane Rawlings)
If references are entirely missing, you can add them using this form.